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ABSTRACT 
 The D3R Grand Challenge 2015 was focused on two protein targets: Heat Shock Protein 90 
(HSP90) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4). We used a 
protocol involving a preliminary analysis of the available data in PDB and PubChem BioAssay, 
and then a docking/scoring step using more computationally demanding parameters that were 
required to provide more reliable predictions. We could evidence that different docking software 
and scoring functions can behave differently on individual ligand datasets, and that the flexibility 
of specific binding site residues is a crucial element to provide good predictions. 
 
INTRODUCTION 
The blinded prediction challenges organized by the Drug Design Data Resource (D3R) 
represent unique occasions for our community to evaluate, in “blind” conditions, the current state 
of computer-aided drug discovery technology and the performance of the currently available 
tools and protocols, with a special emphasis on docking and scoring, through the interchange of 
high quality protein-ligand datasets and workflows. 
The D3R Grand Challenge 2015 was focused on two protein targets (Figure 1): Heat Shock 
Protein 90 (HSP90) [1-12] and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 
(MAP4K4) [13-22].  
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Figure 1. Surface representation of the two protein targets included in the D3R Grand Challenge 
2015: (a) HSP90 (PDB code 2JJC) and (b) MAP4K4 (PDB code 4OBO). The binding site, as 
defined for our docking studies, is colored in red. 
 
In Phase 1 the participants were asked to provide affinity predictions for 180 HSP90 ligands 
and pose prediction for 6 of them, as well as pose prediction for 30 MAP4K4 ligands and affinity 
predictions for 18 of them. In Phase 2 the participants were required to provide the same affinity 
predictions as in Phase 1, taking into account the additional structural data released at the end of 
Phase 1. 
Figure 2 shows the chemical structures of compounds from HSP90 dataset for which both 
affinity predictions and pose predictions were required. Their chemical structures are 
representative for the whole dataset, containing three main classes: benzimidazolones [23], 
aminopyrimidines [24], and benzophenone-like. 
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Figure 2. Chemical structures of the 6 HSP90 ligands included in Phase 1 for both pose 
prediction and ranking (the compound HSP044 was ultimately retired from the pose prediction 
analysis). The entire HSP90 dataset, containing 180 ligands used for ranking prediction, is 
depicted in the Electronic Supplementary Material (Figure S1). 
 
The MAP4K4 dataset for which both affinity predictions and pose predictions were required is 
shown in Figure 3. It contains a relatively diverse distribution of chemical groups, some of them 
already described in literature [25-28]. 
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Figure 3. Chemical structures of the 18 MAP4K4 ligands included in Phase 1 for both pose 
prediction and ranking. The entire MAP4K4 dataset, containing 30 ligands used for pose 
prediction, is depicted in the Electronic Supplementary Material (Figure S2). 
 
METHODS 
Protein structures. We found 191 and 8 crystal structures available in the Protein Data Bank 
(PDB) [29] for human HSP90 and MAP4K4, respectively (see the Electronic Supplementary 
Material for the complete list). All ligands, ions and solvent molecules that were present were 
manually removed, then the structures were superimposed on the reference structures provided 
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by the D3R Grand Challenge 2015 organizers (PDB codes 2JJC and 4OBO, respectively) in 
order to conserve the same coordinate system through the whole process. Then, a common center 
of mass of all ligands from these structures was calculated, and defined as the center of the 
binding site (coordinates 1.0, 10.1, 24.9 for HSP90 and -16.1, -5.4, 30.4 for MAP4K4 in the 
coordinate system of the structure provided). The binding sites were considered as spheres with a 
20 Å radius around these points. In the case of MAP4K4, the same eight ligands were used to 
generate a common pharmacophore using MOE v2013.0802 (http://www.chemcomp.com/), 
which was used later for filtering the docking poses. Missing residues in the structure 4AWQ 
(HSP90) were added using Modeller 9v12 [30]. Hydrogen atoms were added using Hermes, the 
graphical interface of Gold v5.2.2 [31] software, prior to docking. 
Ligands. Ligand structures of the HSP90 and MAP4K4 datasets were provided in SMILES 
format and they were converted into three-dimensional MOL2 files using CORINA v3.60 
(http://www.molecular-networks.com/). The stereochemistry of chiral centers was missing in 
several ligands from the MAP4K4 dataset and in this case all possible stereoisomers were 
considered. The protonation state for all compounds was adjusted at physiological pH using 
LigPrep (Schrödinger, http://www.schrodinger.com/).  
Docking. In the preliminary analysis step, several docking software and scoring functions have 
been tested for their ability to reproduce the protein-ligand complexes from the evaluation 
datasets (11 representative structures of HSP90 and 8 structures of MAP4K4, see Electronic 
Supplementary Material for the complete list of PDB structures): Glide (Schrödinger, 
http://www.schrodinger.com/) with the standard precision (SP) scoring function, Gold [31] with 
the GoldScore, ChemScore, ChemPLP and ASP scoring functions, Vina [32] and Autodock [33]. 
As a result of preliminary analysis, Gold with the GoldScore scoring function was used in Phase 
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1 for evaluating both datasets, whereas Glide was used only for the HSP90 dataset. Default 
parameters were used in all cases for docking, except with Gold, where a search efficiency of 
200% was used in order to better explore the conformational space, as well as a limited side-
chain flexibility: Lys58 (HSP90) and Lys54 (MAP4K4) were flexible, and the two flipped 
conformations of Asn51 (HSP90) were considered. In Phase 2, the rescoring of the MAP4K4 
complexes was carried out using Gold with the GoldScore scoring function. 
Graphics. Chemical structures were depicted using CACTVS Chemoinformatics Toolkit 
v3.409 (Xemistry, http://www.xemistry.com/), images for protein structures were generated 
using PyMol 1.8.1 (Schrödinger, http://www.pymol.org/) and histograms were obtained using 
the R package (http://www.r-project.org). 
 
RESULTS AND DISCUSSION 
In this study we followed a general approach specially designed for predictions without prior 
knowledge of the results, which are the conditions generally encountered in real-life projects. 
Therefore, we took advantage of any structural and biochemical data publicly available for the 
target proteins and for the ligands, and we tried to avoid potential problems by taking into 
account all protein conformations described to date and the flexibility of key residues in the 
binding sites. This protocol involves a preliminary analysis of information available in literature 
(structural and enzymatic data), which is used for the evaluation of the best docking software and 
associated scoring function that are adapted for the system to be studied (protein targets and 
ligand datasets). This combination of docking software and scoring function is then used for the 
actual prediction. This approach proved to be highly successful during our participation to the 
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SAMPL3 (2011) [34], SAMPL4 (2013) [35] and CSAR (2014) [36] docking and virtual 
screening challenges. Noteworthy, as for our previous studies [34-36], we use normal docking 
(not virtual screening) parameters, and a search efficiency of 200%. Considering the size and 
conformational flexibility of some ligands included in the D3R Grand Challenge 2015 datasets, 
these parameters are key points required for providing reliable results, especially in the pose 
prediction step, and for a better conformational sampling of docking conformations. 
Preliminary analysis 
We started by identifying the structural data available for the two protein targets (HSP90 and 
MAP4K4) in the Protein Data Bank (PDB) [29] and PubChem BioAssay [37]. This information 
was further used to evaluate several different docking software and scoring functions and to 
identify those that are the most adapted for the given targets in positioning the ligand in the 
binding site and in scoring (or rescoring) the docking poses. 
HSP90. A number of 191 crystal structures of human HSP90 were identified in the PDB, 
containing 225 unique ligands. The three-dimensional structure of protein in these structures is 
well conserved, with the exception of the fragment 99-129 which is very flexible [38] (Figure 4). 
According to the conformation of this fragment, we could cluster these structures in 11 groups 
(see the Electronic Supplementary Material for the complete list of structures included in each 
group). From each group a representative structure was chosen and the ensemble of these 11 
structures was used for further calculations. 
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Figure 4. Representative 11 HSP90 PDB structures superimposed: a) general view, showing a 
very good global conservation of structural features; b) zoom on residues 99-129, highlighting 
the conformational flexibility of this fragment. The structures are represented as follows: 3BMY 
(green), 3VHA (cyan), 2YK9 (magenta), 3OWD (yellow), 4AWQ (wheat), 3WHA (gray), 3T10 
(purple), 2QF6 (orange), 3K99 (pale green), 3T0H (deep teal), 4BQJ (pink). 
 
On the other hand, we could find in PubChem BioAssay 740 compounds with enzymatic data 
for human HSP90. Among them, 670 compounds were active and 70 inactive. The structure 
comparison of the 225 unique ligands from the PDB structures and the 670 active compounds 
from the PubChem BioAssay afforded 50 structures that were common between the two datasets. 
These 50 ligand structures, for which both binding modes and enzymatic data are available, 
were docked into the 11 representative HSP90 structures selected previously using several 
combinations of docking software and scoring functions: Glide with the standard precision (SP) 
scoring function, Gold with the GoldScore, ChemScore, ChemPLP and ASP scoring functions, 
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Vina and Autodock. RMSD values compared with the native ligands from the crystallographic 
structures were calculated for all docking poses. For each combination protein-ligand-(docking 
software)-(scoring function) we have considered the lowest RMSD value and the RMSD value 
of the best ranking pose, in order to evaluate the accuracy of docking and scoring. In these 
conditions, all docking software and scoring functions provided good results for 70% of the 
dataset, whereas Gold with GoldScore scoring function and to a lesser extent Glide performed 
better for the remaining structures from the dataset (Figure 5, left). 
 
 
Figure 5. Performance evaluation of different combinations of docking software and scoring 
functions using the dataset of 50 HSP90 ligands common between PDB and PubChem BioAssay 
(left) and the D3R Grand Challenge 2015 HSP90 dataset containing 180 ligands (right). 
 
MAP4K4. Eight X-ray structures of human MAP4K4 were available in the PDB, showing a 
good conservation of the three-dimensional structure with the exception of a region containing 
the P-loop, which is known to adopt either a "closed" or an "open" conformation (Figure 6). 
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Given the limited availability of structural data and the diversity of structures in the D3R Grand 
Challenge 2015 MAP4K4 dataset, we have generated a pharmacophore using MOE and the 
superposed ligands from the 8 cystal structures (see Figure S4 in the Electronic Supplementary 
Material for the structures of these ligands). This pharmacophore, which contained a single 
pharmacophoric point – a hydrogen bond acceptor able to interact with the backbone NH group 
of Cys108, was further used in Phase 1 to filter the docking poses. 
 
 
Figure 6. The 8 MAP4K4 PDB structures superimposed: a) general view, showing a very 
good global conservation of structural features; b) zoom on the flexible region, highlighting the 
conformational flexibility of the P-loop. The structures are represented as follows: 4OBO 
(green), 4OBP (cyan), 4OBQ (magenta), 4RVT (yellow), 4U43 (gray), 4U44 (purple), 4U45 
(orange), 4ZK5 (wheat). 
 
Phase 1 
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HSP90. The D3R Grand Challenge 2015 HSP90 dataset containing 180 ligands was docked on 
the 11 representative HSP90 structures using Glide with SP scoring function and Gold with the 
four scoring functions mentioned above, in the preliminary analysis step. As the 180 ligands can 
be easily classified according to their chemical structures (aminopyrimidines, benzimidazolones 
and benzophenone-like – see the Electronic Supplementary Material, page S9, for more details) 
and representative binding modes are known for all these three chemical moieties (Figure 7), we 
have used the common substructures between the three ligands from crystallographic structures 
(A13, MEX and 4EU) and the 180 ligands from the HSP90 dataset in order to compute RMSD 
values, using the same approach as in the Preliminary analysis step. For each ligand, we have 
selected the pose displaying the best RMSD (close to zero), regardless the protein structure on 
which docking was performed, then all the ligands were ranked based on their Goldscore. 
 
 
Figure 7. Representative interactions between the protein HSP90 and ligands A13 (a, PDB code 
2QFO), MEX (b, PDB code 3OW6) and 4EU (c, PDB code 4YKY). Ligands are colored in 
magenta, green and cyan, respectively. Hydrogen atoms were omitted for clarity. 
The results are plotted in Figure 5 (right), showing a very good behavior of Gold with all four 
scoring functions on more than 90% of the dataset, whereas Glide provides very deceiving 
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results on the whole dataset. It is noteworthy the big difference in behavior with Glide between 
the Preliminary analysis dataset and the D3R Grand Challenge 2015 dataset, showing the 
sensitivity of this software on the input ligand dataset. This difference is not observed for Gold, 
which produces equally good predictions on the testing and on the D3R Grand Challenge 2015 
datasets. The results obtained with Gold and GoldScore scoring function were submitted as the 
first prediction and those obtained with Glide as the second prediction (the last one being 
expected to behave not very well), in order to evaluate the accuracy of the two extremes. 
This difference between the docking programs might be due, at least in part, to the flexibility 
of the Lys58 residue in HSP90, which was taken into account with Gold and treated as rigid with 
Glide, Vina and Autodock. The flexibility of this residue seems to be of crucial importance 
during the docking process, since Gold with rigid side chain of Lys58 provides very bad RMSD 
values with the D3R Grand Challenge 2015 HSP90 dataset, comparable with those obtained for 
Glide (Figure 5, right).  
In the pose prediction section of the challenge were included six HSP90 ligands (HSP044, 
HSP044, HSP073, HSP164, HSP175 and HSP179), for which we have submitted the docking 
conformations corresponding to the best score from the calculations presented above. For four of 
them (HSP044, HSP044, HSP175 and HSP179) we have also submitted a second conformation, 
which presented a significantly different binding mode. At the end of Phase 1 were released the 
crystallographic structures of HSP90 complexes containing the six ligands proposed for pose 
prediction. A comparison of our docking poses with the best score and the crystallographic 
conformations is provided in Figure 8. We had very good predictions for the first four ligands, 
with the exception of the pyridylsulfonyl group in HSP044, and a good overall ligand 
orientation, but some different interactions with the binding site for HSP175 and HSP179. This 
 14 
resulted into a mean RMSD of 1.48 Å for the best score conformations, and a mean RMSD of 
1.20 Å for the lowest RMSD poses. 
 
Figure 8. Comparison of our docking poses (green) with crystal structure conformations of 
HSP90 ligands (magenta) HSP040 (a), HSP044 (b), HSP073 (c), HSP164 (d), HSP175 (e) and 
HSP179 (f). 
 
MAP4K4. The protocol used for MAP4K4 was identical with those used for HSP90 (docking 
and scoring), with the exception of an additional pharmacophore-based post-docking filtering 
step. All 8 MAP4K4 crystal structures available were used for docking, using Gold with the 
GoldScore scoring function. The analysis of the docked ligand poses was carried in two steps. 
The first filtering was done using the pharmacophore generated in a previous step, in order to 
retain those poses that establish the interactions that are essential for the biological activity. 
When several different poses were compatible with the pharmacophore, the pose(s) that establish 
the maximum number of favorable interactions with the rest of the binding site were selected for 
submission. The GoldScore value for the best pose of each ligand selected above was then 
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retrieved and used for ranking. The analysis of the Phase 1 submission showed that our 
prediction reproduced moderately well the experimental affinities data, with values of 0.46 and 
0.33 for Pearson R and Kendall Tau, respectively, which ranks our Phase 1 MAPK4K scoring 
submission ex-aequo on the 3th-4th positions out of 76 submissions (see Figure S5 in the 
Electronic Supplementary Material). 
For the pose prediction challenge we have submitted the docking pose corresponding to the 
best score for each ligand. The crystallographic structures of the 30 MAP4K4 ligands included in 
the pose prediction challenge that were released at the end of Phase 1 showed two binding 
patterns for which representative examples are shown in Figure 9. In the first case (representative 
for 11 ligands), the binding mode was already known and generally it was correctly predicted. In 
the second (representative for 17 ligands), a previously unknown binding mode is present and 
this one was generally not well predicted. There are also 2 ligands (MAP04 and MAP17) that 
interact with Cys108 only through crystallographic water molecules and for which the docking 
poses were also incorrect. We can therefore assume that in the last two cases our analysis of 
docking results was biased by the limited availability of structural information regarding the 
interaction of this protein with different families of ligands. The direct consequence of this is the 
relatively high overall mean RMSD values of our predictions compared with the experimental 
coordinates (4.64 Å and 4.32 Å, for the best scoring poses and for lowest-RMSD poses, 
respectively, see Figure 10). 
A tentative explanation for the good ranking prediction of the MAP4K4 ligands while the 
positioning of these ligands in the binding site is relatively poor might be related to the fact that 
the key interactions of the ligand with the binding site are reproduced in the predictions, but not 
with the same atoms as in the crystal structure. In these conditions, the energy of the protein-
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ligand interaction is relatively well evaluated, in spite of important differences in binding 
geometries. 
 
Figure 9. Comparison of our docking poses (green) with crystal structure conformations of 
representative MAP4K4 ligands (magenta) MAP14 (a) and MAP26 (b). 
 
Phase 2 
HSP90. As we have already taken into account the protein flexibility in the Preliminary 
analysis and Phase 1 steps, the release of the 6 new HSP90 crystal structures did not bring any 
new structural information, and therefore our submission for Phase 2 (ligand ranking prediction) 
was identical with the one from Phase 1. 
MAP4K4. In Phase 2 we have only rescored the 30 protein-ligand MAP4K4 complexes that 
were released at the end of Phase 1, using Gold with GoldScore scoring function. All ligands 
were then ranked according to their best GoldScore value, from the highest to the lowest. The 
performance of scoring using crystal structures of the complexes (Phase 2) was reasonably good, 
with values of 0.45 and 0.34 for Pearson R and Kendall Tau, respectively, which are very similar 
with those obtained using docking poses (Phase 1). 
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Figure 10 shows a comparison of mean RMSD values for all pose prediction submissions of 
the D3R Grand Challenge 2015. Our submissions (for which the results were obtained in both 
cases using Gold with GoldScore scoring function) were ranked in the 7th position out of 42 for 
HSP90 and in the 5th position out of 27 for MAP4K4. 
 
 
Figure 10. Mean RMSD of our pose prediction (red) for HSP90 (left) and MAP4K4 (right) 
compared to the other submissions (blue) from the D3R Grand Challenge 2015. The red and blue 
values represent the mean RMSD for the first ranked pose, whereas the light red and light blue 
values correspond to the mean RMSD of the lowest-RMSD pose. A pose prediction section was 
included only in the Phase 1 of the challenge. 
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An overview of the ligand scoring submissions from Phase 2 is presented in Figure 11 (see 
Figure S5 in the Electronic Supplementary Material for the corresponding Phase 1 results). Our 
HSP90 and MAP4K4 submissions prepared with Gold and GoldScore scoring function were 
ranked 29th out of 59 and 2nd out of 46, whereas, as expected, the HSP90 submission prepared 
with Glide was ranked on the last, 59th position. 
 
 
Figure 11. Performance of Phase 2 ranking submissions (Pearson R in blue and Kendall Tau in 
light blue) for the HSP90 (left) and MAP4K4 (right) D3R Grand Challenge 2015 datasets. The 
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best predictions are those with values closest to 1. Our submissions are colored in red and light 
red, respectively. 
Looking retrospectively, the quality of our predictions, at least for the MAP4K4 target, 
suffered from the use of a pharmacophore filtering that was not fuzzy enough, therefore missing 
conformations that might have been correct. All the MAP4K4 ligands interacting with Cys108 in 
the protein-ligand complexes available at the time of the D3R Grand Challenge 2015, which 
were used for building the pharmacophore, had the hydrogen bond acceptor in exactly the same 
region of space, whereas the crystal structures released during the challenge showed a wider 
spatial distribution for the partners involved in this interaction. 
We consider that the ranking of ligands can be greatly improved by using post-docking 
processing, especially by using free energy calculations. In addition to a more reliable evaluation 
of the affinity between protein and ligand, this post-docking processing can also identify and 
correct small deviations in the docking poses, take into account the influence of water molecules 
and of fully flexible protein, etc. Although these techniques require more important 
computational resources, they are fully justified by the potential benefits in providing better 
predictions and we intend to pursue our future research in this direction. 
 
CONCLUSIONS 
In this study we used a protocol involving a preliminary analysis of the available data in PDB 
and PubChem BioAssay, and then a docking/scoring step using more computationally 
demanding parameters that were required to provide more reliable predictions. We could 
evidence that different docking software and scoring functions can behave differently on 
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individual ligand datasets, and that the flexibility of specific binding site residues is a crucial 
element to provide good predictions. 
Electronic Supplementary Material. The Electronic Supplementary Material contains the 
chemical structures of different datasets mentioned in the main text, as well as the performance 
of ligand scoring predictions from Phase 1 submissions. 
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Protein Data Bank (PDB) structures used for the preliminary analysis 
 
HSP90: 
191 structures were available in the PDB for human HSP90 at the moment when the D3R Grand Challenge 
2015 took place. They were organized in 11 distinct groups, according to the conformation of the fragment 
99-129. The representative structure for each group (based on the crystal structure resolution and lack of 
missing residues) is colored in red. 
Group 1: 1uy6, 1uy7, 1uy8, 1uy9, 1uyc, 1uyd, 1uye, 1uyf, 1uyg, 1uyh, 1uyi, 1uyk, 1uym, 2fwy, 2fwz, 
2qg2, 2wi4, 2wi7, 2xds, 2xdu, 2ye7, 2ye8, 2yee, 2yei, 2yej, 2yjx, 2yk2, 2yk9, 2ykb, 2ykc, 2yke, 2yki, 2ykj, 
3b25, 3d0b, 3ft8, 3hyy, 3hz1, 3hz5, 3inw, 3inx, 3mnr, 3nmq, 3o0i, 3qdd, 3qtf, 3r91, 3r92, 3rkz, 3wq9, 4cwf, 
4cwn, 4cwo, 4cwp, 4cwq, 4cwr, 4cws, 4cwt, 4eft, 4efu, 4hy6, 4l8z, 4l90, 4l91, 4lwe, 4nh7, 4nh8, 4o04, 
4o05, 4o07, 4o09, 4o0b, 4r3m, 4u93, 4xip, 4xiq, 4xir, 4xit 
Group 2: 1uyl, 1yer, 2bsm, 2bt0, 2ccs, 2cct, 2ccu, 2jjc, 2uwd, 2vci, 2vcj, 2wi1, 2wi2, 2wi3, 2wi5, 2xab, 
2xdl, 2ye2, 2ye3, 2ye4, 2ye5, 2ye6, 2ye9, 2yea, 2yeb, 2yec, 2yed, 2yeg, 2yeh, 2yi0, 2yi6, 2yi7, 2yjw, 3b24, 
3bm9, 3ft5, 3hhu, 3owb, 3t0h, 4eeh, 4egh, 4fcp, 4fcq, 4l94, 4lwf, 4lwg, 4lwh, 4lwi 
Group 3: 1byq, 1yc3, 1yes, 1yet, 2byh, 2byi, 2xdx, 2xht, 2xhx, 2xjg, 2xjx, 2xk2, 3b27, 3r4m, 3r4o, 3t0z, 
3vha, 3vhc, 4b7p, 4egi 
Group 4: 1osf, 2xdk, 2xjj, 2yef, 3eko, 3ekr, 3hek, 3k97, 3k98, 3r4n, 3r4p, 3rlp, 3rlq, 3rlr, 3t10, 3t1k, 3t2s, 
3vhd, 4egk, 4jql 
Group 5: 1yc1, 1yc4, 2bz5, 2qfo, 2qg0, 2yi5, 3b26, 3b28, 3hyz, 3ow6, 3tuh, 3wha, 4fcr, 4l93, 4w7t 
Group 6: 2wi6, 2xhr, 3bmy 
Group 7: 4awo, 4awp, 4awq 
Group 8: 4bqj 
Group 9: 3owd 
Group 10: 3k99 
Group 11: 2qf6 
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MAP4K4: 
8 structures were available in the PDB for human MAP4K4 at the moment when the D3R Grand Challenge 
2015 took place: 4obo, 4obp, 4obq, 4rvt, 4u43, 4u44, 4u45, 4zk5. 
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Figure S1. Chemical structures of the entire HSP90 dataset, containing 180 ligands used for ranking prediction. 
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HSP90 ligands regroupment according to their chemical structure: 
Aminopyrimidines: HSP063, HSP064, HSP065, HSP066, HSP068, HSP069, HSP070, HSP071, HSP072, 
HSP073, HSP074, HSP075, HSP076, HSP077, HSP078, HSP079, HSP080, HSP081, HSP082, HSP083, 
HSP084, HSP085, HSP086, HSP087, HSP088, HSP089, HSP090, HSP091, HSP092, HSP093, HSP094, 
HSP095, HSP096, HSP097, HSP098, HSP099, HSP100, HSP101, HSP102, HSP103, HSP104, HSP105, 
HSP106, HSP107, HSP108, HSP110, HSP111, HSP112, HSP113, HSP114, HSP115, HSP116, HSP117, 
HSP118, HSP119, HSP120, HSP125, HSP126, HSP147, HSP157, HSP172, HSP179 
Benzimidazolones: HSP001, HSP002, HSP003, HSP004, HSP005, HSP006, HSP007, HSP008, HSP009, 
HSP010, HSP011, HSP012, HSP013, HSP014, HSP015, HSP016, HSP017, HSP018, HSP019, HSP020, 
HSP021, HSP022, HSP023, HSP024, HSP025, HSP026, HSP027, HSP028, HSP029, HSP030, HSP031, 
HSP032, HSP033, HSP034, HSP035, HSP036, HSP037, HSP038, HSP039, HSP040, HSP041, HSP042, 
HSP043, HSP044, HSP045, HSP046, HSP047, HSP048, HSP049, HSP050, HSP051, HSP052, HSP053, 
HSP054, HSP055, HSP056, HSP057, HSP058, HSP059, HSP060, HSP061 
Benzophenone-like: HSP122, HSP127, HSP128, HSP129, HSP130, HSP131, HSP132, HSP133, HSP134, 
HSP136, HSP137, HSP138, HSP139, HSP140, HSP141, HSP142, HSP143, HSP144, HSP146, HSP148, 
HSP149, HSP150, HSP152, HSP154, HSP158, HSP159, HSP160, HSP161, HSP162, HSP163, HSP164, 
HSP166, HSP167, HSP168, HSP169, HSP170, HSP171, HSP173, HSP174, HSP175, HSP176, HSP177, 
HSP178, HSP180, HSP181, HSP182, HSP183 
Miscellaneous: HSP121, HSP123, HSP124, HSP135, HSP145, HSP151, HSP153, HSP155, HSP156, 
HSP165 
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Figure S2. Chemical structures of the entire MAP4K4 dataset, containing 30 ligands used for pose prediction. 
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Figure S3. Chemical structures of HSP90 ligands found in the PDB that are also present in PubChem BioAssay 
with activity data. The compound names are the PDB ligand codes. 
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Figure S4. Chemical structures of MAP4K4 ligands found in the PDB. Compound names include the PDB ligand code and the 
PDB code of the structure containing the ligand. 
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Figure S5. Performance of Phase 1 ranking submissions (Pearson R in blue and Kendall Tau in light blue) for the 
HSP90 (left) and MAP4K4 (right) datasets. The best predictions are those with values closest to 1. Our submissions 
are colored in red and light red, respectively. 
 
 
 
 
